Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine‐, mycophenolate sodium‐, or everolimus‐based low‐dose immunosuppressive therapy
- 4 May 2017
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 19 (3)
Abstract
Background: It remains unclear whether overall degree of immunosuppression or specific effects of individual immunosuppressive agents are causal for increased occurrence of BK polyomavirus (BKPyV) infection in renal transplant recipients (RTR).Methods: A prospective, multicenter, open‐label randomized controlled trial in 361 de novo RTR was performed. A total of 224 RTR were randomized at 6 months into three treatment groups with dual therapy consisting of prednisolone (Pred) plus either cyclosporine (CsA), mycophenolate sodium (MPS), or everolimus (EVL). Primary outcomes were incidence of BK viruria, BK viremia, and BKPyV‐associated nephropathy (BKVAN).Results: From 6 months, incidence of BK viruria in the MPS group (43.6%) was significantly higher than in the other groups (CsA: 16.9%, EVL: 19.8%) (P=.003). BKVAN was diagnosed in 3 patients, all treated with MPS (7.8%, P=.001). Longitudinal data analysis showed a lower BKPyV load and a significantly faster clearance of BK viruria in the CsA group compared to the MPS group (P=.03).Conclusions: Treatment with MPS was associated with an increased incidence of BK viruria. Dual immunosuppressive therapy with CsA and Pred was associated with the lowest rate of BKPyV replication and the fastest clearance of the virus.Keywords
This publication has 36 references indexed in Scilit:
- BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibitionBMC Nephrology, 2013
- Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of AlloimmunityJournal of Immunology Research, 2013
- Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrierClinical Journal of Gastroenterology, 2013
- Polyomavirus BK Replication in De Novo Kidney Transplant Patients Receiving Tacrolimus or Cyclosporine: A Prospective, Randomized, Multicenter StudyAmerican Journal of Transplantation, 2012
- Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapyHepatology, 2011
- Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantationClinical and Experimental Immunology, 2011
- Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure MeasurementsTransplantation, 2010
- A Suppressive Effect of Cyclosporine A on Replication and Noncoding Control Region Activation of Polyomavirus BK VirusTransplantation, 2010
- Risk factors for polyoma virus nephropathyNephrology Dialysis Transplantation, 2008
- Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus ReplicationTransplantation, 2008